ArticleHuman mutation2026
Single-Cell and Machine Learning Analyses Identify MYDGF as an Immune-Related Biomarker Associated With the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell transcriptomics and machine learning methods are increasingly used to identify immune-related biomarkers in solid tumors, yet their combined application to microenvironment-related drivers of therapeutic resistance in clear cell renal cell carcinoma (ccRCC) is still limited. Here, we investigated the biological and clinical significance of myeloid-derived growth factor (MYDGF) through an integrative strategy spanning single-cell profiling, bulk multiomics, and functional validation. Analysis of scRNA-seq data (GSE156632) revealed that MYDGF is preferentially detected in malignant epithelial subpopulations and associated with the composition of myeloid and lymphoid compartments. Integration with TCGA-KIRC transcriptomic and clinical datasets demonstrated strong associations between MYDGF expression and immune-checkpoint activation, immune dysfunction signatures, and PI3K/AKT-MAPK pathway activity. Tumors with high MYDGF expression exhibited an immune-infiltrated yet functionally impaired microenvironment and were predicted to show reduced responsiveness to immune checkpoint blockade. Differential expression and enrichment analyses further highlighted MYDGF-associated genes involved in inflammatory, extracellular, and receptor-binding functions. A machine learning pipeline using LASSO Cox regression identified a preliminary 19-gene MYDGF-related prognostic gene set that requires further validation. Functional experiments confirmed that MYDGF knockdown suppressed proliferation, migration, and invasion in ccRCC cells. Overall, our analyses characterize MYDGF as a microenvironment-related biomarker linked to immune-associated features, signaling-associated alterations, and adverse prognosis in ccRCC. These results nominate MYDGF as a candidate prognostic biomarker and show the value of pairing single-cell resolution with computational modeling for biomarker discovery in renal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.